Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT3 | Q9Y243 | 6/20 | 0.41 |
| ▸ | AKT2 | P31751 | 5/20 | 0.41 |
| ▸ | AKT1 | P31749 | 4/20 | 0.41 |
| ▸ | BRD4 | O60885 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | ATF4 | P18848 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16151898 | 1.00 | AKT3 (0.41) | AKT3AKT2AKT1BRD4LMNA | |
| SCHEMBL13011556 | 1.00 | AKT3 (0.41) | AKT3AKT2AKT1BRD4LMNA | |
| SCHEMBL12188538 | 1.00 | AKT3 (0.41) | AKT3AKT2AKT1BRD4LMNA | |
| SCHEMBL684829 | 0.94 | BRD4 (0.44) | AKT3AKT2AKT1BRD4LMNA | |
| SCHEMBL16264283 | 0.88 | GAA (0.40) | AKT3AKT2AKT1BRD4LMNA | |
| SCHEMBL16151903 | 0.88 | BRD4 (0.40) | BRD4LMNAMEN1KMT2AHSP90AA1 | |
| SCHEMBL12188493 | 0.88 | AKT3 (0.48) | AKT3AKT2AKT1LMNANPC1 | |
| SCHEMBL17424833 | 0.87 | AKT3 (0.40) | AKT3AKT2AKT1BRD4LMNA | |
| SCHEMBL680938 | 0.87 | BRD4 (0.43) | AKT3AKT2AKT1BRD4LMNA | |
| SCHEMBL14267027 | 0.87 | BRD4 (0.43) | AKT3AKT2AKT1BRD4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160235754-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-08-18 | — | — | US | disclosed |
| US-9359340-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as Akt protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160152606-A9 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. | 2016-06-02 | — | — | US | disclosed |
| US-9303040-B2 | Substituted piperazines as AKT inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150191479-A1 | DIHYDROFURO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2015-07-09 | — | — | US | disclosed |
| US-20140349997-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140349996-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2014-11-27 | — | — | US | disclosed |
| US-8853199-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8846681-B2 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20120329808-A1 | DIHYDROTHIENO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-12-27 | — | — | US | disclosed |
| EP-2049500-B1 | CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2011-09-07 | — | — | EP | disclosed |
| EP-2049546-B1 | DIHYDROFURO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2010-12-29 | — | — | EP | disclosed |
| US-20080058327-A1 | 4-piperazinyl-5H-6,7-dihydrocyclopenta(d)pyrimidines; Hyperproliferative diseases such as cancer | GENENTECH, INC. | 2008-03-06 | — | — | US | disclosed |
| WO-2008006040-A1 | HYDROXYLATED AND METHOXYLATED CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058327-A1 | 4-piperazinyl-5H-6,7-dihydrocyclopenta(d)pyrimidines; Hyperproliferative diseases such as cancer | PIK3CA, DPYD, CDK2 | AKT3 27/4885AKT2 23/4885AKT1 33/4885 |
| US-20160235754-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | AKT3 3/4885AKT2 2/4885AKT1 1/4885 |
| US-20140349997-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | AKT3 4/4885AKT2 2/4885AKT1 1/4885 |
| US-20120329808-A1 | DIHYDROTHIENO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | DTYMK, TK1, PIK3CA | AKT3 5/4885AKT2 6/4885AKT1 7/4885 |
| US-20150191479-A1 | DIHYDROFURO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | DPYD, DTYMK, PIK3CA | AKT3 10/4885AKT2 8/4885AKT1 9/4885 |
| US-20160152606-A9 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | AKT3 4/4885AKT2 2/4885AKT1 1/4885 |
| US-20140349996-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | AKT3 8/4885AKT2 4/4885AKT1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.